Skip to main content
PMC home page
Current Therapeutic Research, Clinical and Experimental logoLink to Current Therapeutic Research, Clinical and Experimental
. 2005 May;66(3):212–221. doi: 10.1016/j.curtheres.2005.06.006

Levetiracetam in the preventive treatmentof transformed migraine: A prospective, open-label, pilot study

Alan M Rapoport 1,2, Fred D Sheftell 2,3, Stewart J Tepper 2,4, Marcelo E Bigal 2,5,**
PMCID: PMC3964555  PMID: 24672124

Abstract

Background:

Most preventive agents used for transformed migraine (TM)have not been studied specifically for the treatment of this syndrome. Open-label trials have demonstrated the effectiveness of levetiracetam in the treatment of refractory headaches.

Objective:

The aim of this study was to assess the effectiveness and tolerabilityof levetiracetam in the preventive treatment of refractory TM.

Methods:

This prospective, open-label, pilot study was conducted at TheNew England Center for Headache, Stamford, Connecticut. We included patients aged ≥ 18 years with refractory TM according to the criteria proposed by Silberstein et al. All participants had failed on at least 1 but not more than 3 preventive drugs. Other preventive drugs were allowed if they had been received at a stable dose for > 30 days. The dosage of the levetiracetam tablets ranged from 1000 to 3000 mg/d in 2 divided doses. The treatment phase lasted 3 months. The primary end point was headache frequency (expressed as the number of headache days per month), and the secondary end point was the frequency of moderate or severe headache (d/mo). Other end points were headache score, Migraine Disability Assessment (MIDAS) Questionnaire score, and Headache Impact Test (HIT-6) score. Statistical analyses were performed in the intent-to-treat (ITT) population (patients who received at least 1 dose of study medication) using data subjected to the last-observation-carried-forward algorithm. We also conducted per-protocol (PP) analyses in patients who completed the study.

Results:

The ITT population consisted of 36 patients (26 women, 10 men;mean [SD] age, 46.5 [17.4] years). The mean headache frequency at baseline was 24.9 d/mo, and a significant reduction in headache frequency was obtained at l, 2, and 3 months of treatment (19.4, 18.4, and 16.2 d/mo, respectively; all, P < 0.001 Reproduction in whole or part is not permitted. vs baseline). At baseline, the mean number of moderate or severe headache days was 16.8 d/mo compared with 13.2, 11.9, and 9.7 d/mo at 1, 2, and 3 months, respectively (P=NS, <0.01, and <0.01, respectively). The mean MIDAS score was significantly reduced at 3 months compared with baseline (40.8 vs 62.8 d/mo; P = 0.01). The mean HIT-6 score was 59.4 at 3 months versus 63.4 at baseline (P < 0.01). In the PP population, the mean (SD) headache frequency was reduced from 26.1 (4.1) d/mo at baseline to 14.3 (4.8) d/mo at the end of the study (P < 0.001). The mean (SD) headache score was reduced from 51.3 (17.1) at baseline to 34.0 (22.0) at 3 months (P < 0.016).

Conclusion:

The results of this study in patients with TM support the role of levetiracetam in the preventive treatment of refractory TM.

Key words: levetiracetam, transformed migraine, chronic daily headache, preventive treatment, prevention

Full Text

The Full Text of this article is available as a PDF (573.6 KB).

References

  • 1.Mathew N.T. Medication misuse headache. Cephalalgia. 1998;18(Suppl 21):34–36. doi: 10.1177/0333102498018s2109. [DOI] [PubMed] [Google Scholar]
  • 2.Solomon S., Lipton R.B., Newman L.C. Evaluation of chronic daily headache—comparison to criteria for chronic tension-type headache. Cephalalgia. 1992;12:365–368. doi: 10.1111/j.1468-2982.1992.00365.x. [DOI] [PubMed] [Google Scholar]
  • 3.Bigal M.E., Sheftell F.D., Rapoport A.M. Chronic daily headache in a tertiary care population: Correlation between the International Headache Society diagnostic criteria and proposedrevisions of criteria for chronic daily headache. Cephalalgia. 2002;22:432–438. doi: 10.1046/j.1468-2982.2002.00384.x. [DOI] [PubMed] [Google Scholar]
  • 4.Silberstein S.D., Lipton R.B., Sliwinski M. Classification of daily and near-daily headaches: Field trial of revised IHS criteria. Neurology. 1996;47:871–875. doi: 10.1212/wnl.47.4.871. [DOI] [PubMed] [Google Scholar]
  • 5.Spierings E.L. Treatment and outcome of chronic daily headache. Otolaryngol Clin North Am. 2003;36:1109–1117. doi: 10.1016/s0030-6665(03)00133-6. [DOI] [PubMed] [Google Scholar]
  • 6.Freitag F.G. Divalproex sodium extended-release for the prophylaxis of migraine headache. Expert Opin Pharmacother. 2003;4:1573–1578. doi: 10.1517/14656566.4.9.1573. [DOI] [PubMed] [Google Scholar]
  • 7.Brandes J.L., Saper J.R., Diamond M., for the MIGR 002 Study Group Topiramate for migraine prevention: A randomized controlled trial. JAMA. 2004;291:965–973. doi: 10.1001/jama.291.8.965. [DOI] [PubMed] [Google Scholar]
  • 8.Welch K.M., D'Andrea G., Tepley N. The concept of migraine as a state of central neuronal hyperexcitability. Neurol Clin. 1990;8:817–828. [PubMed] [Google Scholar]
  • 9.Goadsby P.J. Migraine, aura, and cortical spreading depression: Why are we still talking about it? Ann Neurol. 2001;49:4–6. doi: 10.1002/1531-8249(200101)49:1<4::aid-ana3>3.0.co;2-w. [DOI] [PubMed] [Google Scholar]
  • 10.Lance J.W., Lambert G.A., Goadsby P.J., Duckworth J.W. Brainstem influences on the cephalic circulation: Experimental data from cat and monkey of relevance to the mechanism of migraine. Headache. 1983;23:258–265. doi: 10.1111/j.1526-4610.1983.hed2306258.x. [DOI] [PubMed] [Google Scholar]
  • 11.Welch K.M., Nagesh V., Aurora S.K., Gelman N. Periaqueductal gray matter dysfunction in migraine: Cause or the burden of illness? Headache. 2001;41:629–637. doi: 10.1046/j.1526-4610.2001.041007629.x. [DOI] [PubMed] [Google Scholar]
  • 12.Ben-Menachem E. Levetiracetam: Treatment in epilepsy. Expert Opin Pharmacother. 2003;4:2079–2088. doi: 10.1517/14656566.4.11.2079. [DOI] [PubMed] [Google Scholar]
  • 13.Drake M.E., Greathouse N.I., Armentbright A.D., Renner J.B. Levetiracetam for preventive treatment of migraine. Cephalalgia. 2001;21:373. Abstract. [Google Scholar]
  • 14.Krusz J.C. Levetiracetam as prophylaxis for resistant headaches. Cephalalgia. 2001;21:373. Abstract. [Google Scholar]
  • 15.Lipton R.B., Stewart W.E. AstraZeneca Pharmaceuticals LP; Wilmington, De: 2002. April 8, 2005. Migraine Disability Assessment (MIDAS) Questionnaire.http://www.midasmigraine.net. Available at: Accessed. [Google Scholar]
  • 16.Headache Impact Test (HIT-6), version 1.1. QualityMetric, Inc, and GlaxoSmithKline Group of Companies; Research Triangle Park, NC: 2001. April 8, 2005. http://www.headachetest.com [Google Scholar]
  • 17.Mathew N.T. Transformed migraine. Cephalalgia. 1993;13(Suppl 12):78–83. doi: 10.1177/0333102493013S1217. [DOI] [PubMed] [Google Scholar]
  • 18.Mathew N.T., Reuveni U., Perez F. Transformed or evolutive migraine. Headache. 1987;27:102–106. doi: 10.1111/j.1526-4610.1987.hed2702102.x. [DOI] [PubMed] [Google Scholar]
  • 19.Bigal M.E., Rapoport A.M., Lipton R.B. Assessment of migraine disability using the migraine disability assessment (MIDAS) questionnaire: A comparison of chronic migraine with episodic migraine. Headache. 2003;43:336–342. doi: 10.1046/j.1526-4610.2003.03068.x. [DOI] [PubMed] [Google Scholar]
  • 20.Magnusson J.E., Riess C.M., Becker W.J. Effectiveness of a multidisciplinary treatment program for chronic daily headache. Can J Neurol Sci. 2004;31:72–79. doi: 10.1017/s0317167100002869. [DOI] [PubMed] [Google Scholar]
  • 21.Mathew N.T., Ali S. Valproate in the treatment of persistent chronic daily headache. An open label study. Headache. 1991;31:71–74. doi: 10.1111/j.1526-4610.1991.hed3102071.x. [DOI] [PubMed] [Google Scholar]
  • 22.Edwards K.R., Dreyer M.D. Botulinum toxin type A (Botox) for chronic daily headache. Headache. 2002;42:429. Abstract. [Google Scholar]
  • 23.Shuaib A., Ahmed F., Muratoglu M., Kochanski P. Topiramate in migraine prophylaxis: A pilot study. Cephalalgia. 1999;19:379–380. Abstract. [Google Scholar]
  • 24.Smith T.R. Zonisamide improves total headache times and headache index in refractory chronic daily headaches, a retrospective case series. Headache. 2002;42:434. Abstract. [Google Scholar]
  • 25.Lake A.E., Saper J.R., Spierings E.L. Chronic daily headache prophylaxis with tizanidine: A double-blind multicenter study outcome study. Headache. 2002;42:430. doi: 10.1046/j.1526-4610.2002.02122.x. Abstract. [DOI] [PubMed] [Google Scholar]
  • 26.Rapoport A.M., Bigal M.E., Volcy M. Naratriptan in the preventive treatment of refractory chronic migaine: A review of 27 cases. Headache. 2003;43:482–489. doi: 10.1046/j.1526-4610.2003.03094.x. [DOI] [PubMed] [Google Scholar]
  • 27.Saper J.R., Lake A.E., Hamel R.L. Daily opioid therapy in the treatment of refractory headache. Neurology. 2004;62:1687–1694. [Google Scholar]
  • 28.Silberstein S.D. Divalproex sodium in headache: Literature review and clinical guidelines. Headache. 1996;36:547–555. doi: 10.1046/j.1526-4610.1996.3609547.x. [DOI] [PubMed] [Google Scholar]

Articles from Current Therapeutic Research, Clinical and Experimental are provided here courtesy of Elsevier

RESOURCES